【摘要】 多黏菌素B(1)是由多黏芽孢杆菌(Paenibacillus polymyxa)产生的一类碱性多肽类抗菌药，主要成分包括B1、B2、B3和B1-I，对耐药菌感染的治疗效果显著。为了提高1产量，该研究以多黏芽孢杆菌SIPIPB-1[发酵单位(837±50) mg/L]为出发菌株，采用传统诱变法选育，获得了突变菌株SIPIPB-N14[发酵单位(1297±60) mg/L]。随后优化了SIPIPB-N14的发酵培养基和发酵工艺。在优化发酵条件下，1在5L发酵罐中的发酵产量可达(1681±25) mg/L，其中B1、B2、B3、B1-I的比例分别为(74.5±1.1)%、(20.4±0.8)%、(1.3±0.3)%、(3.0±0.1)%，符合原料药组分的要求，为工业化生产提供了试验数据。更多还原

【Abstract】 Polymyxin B(1), a basic polypeptide antibacterial drug, was mainly produced by Paenibacillus polymyxa and showed significant effects on treatment of drug-resistant bacterial infections. The main components of 1 include B1, B2, B3, and B1-I. To increase the yield of 1, this study with P. polymyxa SIPI PB-1[fermentation unit:(837±50)mg/L] as the starting strain, obtained the mutant strain SIPI PB-N14[fermentation unit:(1 297±60)mg/L]through traditional mutagenesis and selection. Then, the fermentation medium and fermentation process of SIPI PB-N14were optimized. Under the optimized fermentation conditions, the fermentation yield of 1 in a 5 L fermenter could reach(1 681±25)mg/L, of which the proportions of B1, B2, B3, and B1-I were(74.5±1.1)%,(20.4±0.8)%,(1.3±0.3)%, and(3.0±0.1)%, which met the requirements of API components and provided test data for industrial production.更多还原